Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sumitomo Corporation
Highlights of year-end application submissions including candidates from AstraZeneca, BioMarin, Lilly, MorphoSys, and Seattle Genetics.
Acorda buys Civitas and its Parkinson’s candidate for $525 million, ending the latter’s intent to go public. Pharmacyclics and Servier unwind their 2009 agreement to co-develop oncology drug abexinostat.
Device financing dropped more than 40% to $714 million in Q1; Smith & Nephew’s $1.7 billion acquisition of ArthroCare overshadowed acquisitions. Diagnostics companies raised $568 million, a 34% increase over 2013’s final quarter; nonprofits provided assets to diagnostics firms in multiple licensing arrangements.
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.